Clinical trial
Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer
NCT00030602 · University of Maryland, Baltimore, Other · Completed
Key facts
| NCT number | NCT00030602 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer |
| Official title | A Phase 2 Study Of Prostate Specific Antigen-3 (PSA-3) (NSC # 694155) With Montanide (NSC #675756) Vaccination In Patients With Prostate Cancer Recurrent |
| Lead sponsor | University of Maryland, Baltimore, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Biological |
| Interventions | PSA prostate cancer vaccine, incomplete Freund's adjuvant |
| Start date | Jan 1, 2000 |
| Primary completion | Dec 1, 2001 |
| Completion | Dec 1, 2001 |
| First posted | Feb 19, 2004 |
| Last update posted | Nov 5, 2019 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: